1. Two patients on long-term entecavir achieve undetectable HBV DNA. Patient 1 is hepatitis B e antigen positive and undergoes durable e antigen seroconversion; Patient 2 is e antigen negative from the outset. Integrating the persistence of the covalently closed circular DNA (cccDNA) template with the differing relapse behavior of these two groups, how should treatment duration be approached?
A) Both patients can stop therapy immediately once HBV DNA is undetectable, because suppression eradicates cccDNA in both
B) In Patient 1, discontinuation can be considered after durable e antigen seroconversion in the absence of cirrhosis, with monitoring for reactivation; in Patient 2, virological relapse after stopping is nearly universal, so indefinite therapy is the standard
C) Patient 2 can stop safely after one year because e antigen negative disease does not relapse, while Patient 1 must continue indefinitely
D) Both patients require indefinite therapy because e antigen status has no bearing on relapse risk
E) Patient 1 should stop the moment e antigen is lost without waiting for seroconversion, because anti-HBe development is irrelevant to relapse
ANSWER: B
Rationale:
Nucleos(t)ide analogues suppress replication but do not clear cccDNA, so the durability of any off-therapy response depends on the host serologic state. In e antigen positive disease, durable e antigen seroconversion creates a state in which discontinuation can be considered in non-cirrhotic patients, though reactivation monitoring remains necessary. In e antigen negative disease, virological relapse after stopping is nearly universal, making indefinite therapy the standard.
Option A: Option A is incorrect because suppression does not eradicate cccDNA in either patient, so immediate cessation is not safe.
Option C: Option C inverts the relapse behavior: it is e antigen negative disease (Patient 2), not Patient 1, that relapses nearly universally.
Option D: Option D is incorrect because e antigen status does influence the discontinuation decision; it is not irrelevant.
Option E: Option E is incorrect because durable seroconversion (loss of e antigen with development of anti-HBe), not mere e antigen loss, is what permits considering discontinuation.
2. Tenofovir alafenamide has a superior renal and bone safety profile compared with tenofovir disoproxil fumarate because of its lower systemic tenofovir exposure. Yet for a pregnant patient with chronic hepatitis B requiring therapy, tenofovir disoproxil fumarate is often preferred. Integrating the safety-profile reasoning with the clinical decision, what best explains this apparent reversal?
A) Tenofovir alafenamide is teratogenic and absolutely contraindicated in pregnancy
B) Pregnancy abolishes the renal and bone toxicity of tenofovir disoproxil fumarate, removing any reason to prefer tenofovir alafenamide
C) Tenofovir disoproxil fumarate has higher antiviral potency than tenofovir alafenamide and is needed for the higher viral loads of pregnancy
D) Drug selection weighs more than the systemic-exposure safety advantage: tenofovir disoproxil fumarate has substantially more accumulated safety data in pregnancy, so that established reproductive safety experience can outweigh tenofovir alafenamide's exposure-based advantage in this specific population
E) Tenofovir alafenamide cannot suppress HBV during pregnancy because placental enzymes inactivate it
ANSWER: D
Rationale:
The choice in pregnancy illustrates that the systemic-exposure safety advantage of tenofovir alafenamide is only one input into drug selection. Tenofovir disoproxil fumarate has a much larger body of accumulated reproductive safety data, and in pregnancy that established experience can outweigh the exposure-based advantage of the newer agent — which is why tenofovir disoproxil fumarate is often preferred in this population.
Option A: Option A is incorrect because tenofovir alafenamide is not established as teratogenic or absolutely contraindicated; the issue is comparatively limited pregnancy data, not proven harm.
Option B: Option B is incorrect because pregnancy does not abolish tenofovir disoproxil fumarate's toxicities; the preference rests on safety data, not on disappearance of toxicity.
Option C: Option C is incorrect because the two prodrugs have equivalent antiviral efficacy, so superior potency is not the reason.
Option E: Option E is incorrect because tenofovir alafenamide is not inactivated by placental enzymes and does retain antiviral activity; the decision is driven by reproductive safety data.
3. A patient with lymphoma is about to begin rituximab. Serology shows hepatitis B surface antigen negative, hepatitis B core antibody positive (a resolved-infection pattern). Integrating the patient's serologic state with the potency of the planned immunosuppression, what is the most appropriate hepatitis B management?
A) Initiate prophylactic nucleos(t)ide analogue therapy (such as tenofovir alafenamide or entecavir) before rituximab, because anti-CD20 therapy is a high-risk reactivation trigger even in resolved infection
B) No screening or intervention is needed because surface antigen negativity proves the virus is fully eradicated
C) Begin pegylated interferon prophylaxis, because interferon is the preferred agent to prevent reactivation during immunosuppression
D) Delay any decision until HBV DNA becomes detectable, then begin treatment only after reactivation is confirmed
E) Vaccinate against hepatitis B during chemotherapy, which will prevent reactivation of the patient's existing infection
ANSWER: A
Rationale:
Resolved infection (surface antigen negative, core antibody positive) still carries persistent cccDNA that can reactivate, and anti-CD20 agents such as rituximab are among the highest-risk reactivation triggers. Integrating these two facts, the appropriate approach is prophylactic nucleos(t)ide analogue therapy (tenofovir alafenamide or entecavir preferred) started before and continued after the immunosuppressive course, rather than monitoring alone.
Option B: Option B is incorrect because surface antigen negativity does not prove eradication; core antibody positivity reflects prior infection with reactivation potential.
Option C: Option C is incorrect because interferon is not used as reactivation prophylaxis; nucleos(t)ide analogues are the prophylactic agents.
Option D: Option D is incorrect and unsafe: waiting for detectable HBV DNA forfeits the purpose of prophylaxis, since reactivation can progress to acute liver failure.
Option E: Option E is incorrect because vaccination does not prevent reactivation of an existing infection and is not the protective strategy here.
4. A patient with compensated cirrhosis from chronic hepatitis B has been stable on tenofovir for years and asks to stop the medication. Integrating the persistence of viral replication potential with the patient's cirrhotic liver, what is the principal danger of abrupt discontinuation, and how should any planned cessation be handled?
A) There is no danger; cirrhotic patients clear the virus spontaneously once therapy stops
B) The main risk is rebound hypertension, managed by adding a beta-blocker before stopping
C) Abrupt cessation is safe in cirrhosis but dangerous only in non-cirrhotic patients, so no special precaution is needed here
D) The danger is renal recovery occurring too quickly, requiring a slow taper to protect the kidneys
E) Abrupt withdrawal can trigger a severe hepatitis flare from viral rebound, which in a cirrhotic liver risks decompensation; if discontinuation is attempted at all it requires close HBV DNA and alanine aminotransferase monitoring with a careful taper
ANSWER: E
Rationale:
Because nucleos(t)ide analogues suppress but do not eliminate the virus, stopping therapy permits viral rebound. In a cirrhotic patient this rebound can provoke a severe hepatitis flare with risk of hepatic decompensation, so abrupt discontinuation is particularly hazardous; any planned cessation requires close HBV DNA and alanine aminotransferase monitoring with a careful taper.
Option A: Option A is incorrect because cirrhotic patients do not spontaneously clear the virus when therapy stops.
Option B: Option B is incorrect because the risk is a hepatitis flare from viral rebound, not rebound hypertension.
Option C: Option C inverts the risk: cirrhotic patients are at greater, not lesser, danger from withdrawal flares.
Option D: Option D is incorrect because the concern is a hepatitis flare from viral rebound, not overly rapid renal recovery.
5. A patient with hepatitis C and an estimated glomerular filtration rate of 22 mL/min/1.73m2 needs treatment. Integrating sofosbuvir's elimination pathway with this degree of renal impairment, which regimen choice is best supported, and why?
A) A sofosbuvir/velpatasvir regimen at full dose, because sofosbuvir is hepatically cleared and unaffected by renal function
B) A sofosbuvir-based regimen with the dose halved, because the parent drug accumulates and toxicity is dose-linear
C) A sofosbuvir-free regimen such as glecaprevir/pibrentasvir, because sofosbuvir's inactive metabolite GS-331007 is renally eliminated and accumulates significantly when the estimated glomerular filtration rate falls below 30 mL/min/1.73m2
D) Pegylated interferon and ribavirin, because direct-acting antivirals are all contraindicated in renal impairment
E) Any regimen, because renal function has no impact on the pharmacokinetics of hepatitis C antivirals
ANSWER: C
Rationale:
Sofosbuvir is eliminated renally as the inactive metabolite GS-331007, which accumulates significantly when the estimated glomerular filtration rate falls below about 30 mL/min/1.73m2. Integrating this elimination pathway with the patient's severe renal impairment, a sofosbuvir-free regimen such as glecaprevir/pibrentasvir — which requires no dose adjustment in renal impairment — is the best-supported choice.
Option A: Option A is incorrect because sofosbuvir is not hepatically cleared in a way that spares the kidney; its metabolite is renally eliminated and accumulates.
Option B: Option B is incorrect because the issue is metabolite accumulation handled by regimen selection, and simple dose-halving of sofosbuvir is not the established approach.
Option D: Option D is incorrect because effective oral direct-acting antiviral options exist in renal impairment (notably the sofosbuvir-free glecaprevir/pibrentasvir), so reverting to interferon and ribavirin is unnecessary.
Option E: Option E is incorrect because renal function does affect sofosbuvir-containing regimens through metabolite accumulation.
6. A trainee proposes treating hepatitis C with an NS5A inhibitor alone to simplify therapy, reasoning that NS5A inhibitors are highly potent and pan-genotypic. Integrating the potency of NS5A inhibitors with their resistance barrier and that of a partner agent, why is this proposal unsound?
A) NS5A inhibitors are too weak to use even in combination, so monotherapy would simply fail to suppress the virus at all
B) Despite their potency, NS5A inhibitors used alone have a relatively low barrier to resistance; pairing them with a high-barrier agent such as the NS5B nucleotide inhibitor sofosbuvir suppresses emergence of resistant virus, which monotherapy would allow
C) NS5A inhibitors require activation by a co-administered protease inhibitor, so they are pharmacologically inert when given alone
D) Monotherapy is unsound only because of cost, not because of any resistance consideration
E) NS5A inhibitors cannot reach hepatocytes without a sofosbuvir carrier molecule, so the partner drug is needed purely for delivery
ANSWER: B
Rationale:
NS5A inhibitors are potent and broadly active, but used alone they have a relatively low barrier to resistance, so resistant variants can emerge and drive breakthrough. Pairing them with a high-barrier agent — classically the NS5B nucleotide inhibitor sofosbuvir, whose S282T resistance substitution carries a high fitness cost — suppresses the emergence of resistance that monotherapy would permit. The reasoning integrates potency with the differing resistance barriers of the two classes.
Option A: Option A is incorrect because NS5A inhibitors are potent, not too weak to use; the problem is resistance, not lack of antiviral effect.
Option C: Option C is incorrect because NS5A inhibitors are not prodrugs requiring protease-inhibitor activation; they have intrinsic activity.
Option D: Option D is incorrect because the central reason is resistance prevention, not cost.
Option E: Option E is incorrect because NS5A inhibitors reach hepatocytes on their own and do not need sofosbuvir as a delivery carrier.
7. A patient with epilepsy taking carbamazepine, a strong CYP3A4 inducer, is started on glecaprevir/pibrentasvir. Integrating the mechanism of enzyme induction with the metabolic dependence of the protease inhibitor component, what outcome should be anticipated, and what is the correct interpretation?
A) Carbamazepine accelerates clearance of the protease inhibitor, lowering its plasma concentration to subtherapeutic levels and risking virologic failure; this is why strong inducers are an absolute contraindication with protease inhibitor-containing regimens
B) Carbamazepine raises protease inhibitor levels, producing dangerous accumulation that requires a dose reduction
C) The two drugs do not interact because protease inhibitors are not metabolized by CYP3A4
D) Carbamazepine and the protease inhibitor compete for renal excretion, prolonging both half-lives and improving efficacy
E) The interaction causes immediate hepatotoxicity through glutathione depletion, paralleling acetaminophen injury
ANSWER: A
Rationale:
The NS3/4A protease inhibitor component depends on CYP3A4 (and P-glycoprotein) for its disposition. A strong inducer such as carbamazepine increases clearance and lowers the protease inhibitor's plasma concentration to subtherapeutic levels, risking virologic failure and resistance — which is why strong inducers are an absolute contraindication with protease inhibitor-containing regimens. The reasoning integrates the induction mechanism with the drug's metabolic dependence.
Option B: Option B inverts the direction: induction lowers, not raises, drug levels.
Option C: Option C is incorrect because protease inhibitors are indeed CYP3A4 substrates, so the interaction is real.
Option D: Option D is incorrect because the mechanism is hepatic enzyme induction, not competition for renal excretion, and the effect is loss of efficacy, not improvement.
Option E: Option E is incorrect because the interaction reduces drug exposure; it does not cause glutathione-depletion hepatotoxicity, which is the acetaminophen mechanism.
8. A patient with atrial fibrillation maintained on amiodarone needs hepatitis C treatment, and the proposed regimen contains sofosbuvir. Integrating the known interaction with the clinical decision, what is the correct course of action?
A) Proceed with the sofosbuvir regimen and add a rate-controlling agent, since the combination only mildly increases heart rate
B) Substitute ribavirin for sofosbuvir, since ribavirin carries the same bradycardia risk and is interchangeable
C) Proceed without concern, because the amiodarone interaction applies only to NS5A inhibitors, not sofosbuvir
D) Avoid co-administration if possible by selecting a sofosbuvir-free regimen; if a sofosbuvir-containing regimen is unavoidable, it should be used only with continuous cardiac monitoring because the combination risks serious, potentially fatal symptomatic bradycardia
E) Stop amiodarone the same day sofosbuvir is started, since amiodarone is cleared within hours and the risk resolves immediately
ANSWER: D
Rationale:
Amiodarone combined with a sofosbuvir-containing regimen carries a risk of serious, potentially fatal symptomatic bradycardia. Integrating this with the clinical decision, the preferred course is to avoid the combination by choosing a sofosbuvir-free regimen (such as glecaprevir/pibrentasvir); if a sofosbuvir-containing regimen is truly unavoidable, it should be used only with continuous cardiac monitoring.
Option A: Option A is incorrect because the interaction causes dangerous bradycardia, not a mild rate increase, and is not made safe simply by adding a rate-controlling agent.
Option B: Option B is incorrect because ribavirin is not interchangeable with sofosbuvir and is not the source of this bradycardia risk.
Option C: Option C is incorrect because the bradycardia interaction is specifically with sofosbuvir, not with NS5A inhibitors.
Option E: Option E is incorrect because amiodarone has an extremely long half-life (weeks), so stopping it the same day does not eliminate the risk promptly.
9. A patient with hepatitis C and established cirrhosis achieves sustained virologic response at 12 weeks (SVR12). The patient asks whether liver cancer screening can now be stopped. Integrating the meaning of virologic cure with the residual state of the cirrhotic liver, what is the correct counsel?
A) Screening can stop immediately, because SVR12 reverses cirrhosis and eliminates cancer risk entirely
B) Screening can stop after one additional year, because hepatocellular carcinoma risk falls to that of the general population within twelve months of cure
C) Hepatocellular carcinoma surveillance should continue, because although SVR12 is a durable virologic cure that lowers cancer incidence, the residual cirrhosis continues to carry hepatocellular carcinoma risk even after the virus is cleared
D) Screening is no longer indicated because hepatocellular carcinoma occurs only in actively replicating hepatitis C
E) Screening should intensify because clearing the virus accelerates new tumor formation
ANSWER: C
Rationale:
SVR12 is a durable virologic cure that reduces — but does not eliminate — hepatocellular carcinoma incidence, and the structural cirrhosis persists even after the virus is gone. Integrating cure with residual cirrhosis, ongoing hepatocellular carcinoma surveillance is required in patients with advanced fibrosis or cirrhosis after SVR12.
Option A: Option A is incorrect because SVR12 does not fully reverse cirrhosis or abolish cancer risk; partial fibrosis regression may occur but residual risk remains.
Option B: Option B is incorrect because cancer risk in cirrhotic patients does not fall to general-population levels within a year of cure.
Option D: Option D is incorrect because hepatocellular carcinoma can still arise in a cured but cirrhotic liver; it is not confined to actively replicating infection.
Option E: Option E is incorrect because clearing the virus reduces, rather than accelerates, tumor formation; surveillance continues because of residual risk, not because cure promotes cancer.
10. A patient with hepatitis D begins bulevirtide. After two weeks the HDV RNA has fallen only modestly, and the patient worries the drug is failing. Integrating bulevirtide's mechanism with the biology of HDV's dependence on hepatocyte turnover, what is the correct interpretation of this early result?
A) The slow decline confirms treatment failure, and bulevirtide should be stopped immediately
B) The result is unexpected because entry inhibitors produce an immediate collapse in viral load within days
C) The modest early decline indicates resistance has already emerged, requiring a switch to pegylated interferon
D) The result reflects a dosing error, since correctly dosed bulevirtide eliminates HDV RNA within the first week
E) A gradual decline is expected: bulevirtide blocks viral entry at the sodium-taurocholate cotransporting polypeptide rather than acting inside already-infected cells, so its virologic effect develops over time as infected hepatocytes turn over
ANSWER: E
Rationale:
Bulevirtide competitively blocks the sodium-taurocholate cotransporting polypeptide to prevent new hepatocyte entry, but it does not act on virus already inside infected cells. Integrating this mechanism with HDV biology, the virologic effect is expected to develop gradually as already-infected hepatocytes turn over, so a modest decline at two weeks is consistent with the drug working as designed, not failing.
Option A: Option A is incorrect because a slow early decline is the expected pharmacodynamic pattern, not evidence of failure warranting cessation.
Option B: Option B is incorrect because entry inhibitors specifically do not produce an immediate viral collapse; the delayed effect is intrinsic to the mechanism.
Option C: Option C is incorrect because a gradual decline does not indicate resistance.
Option D: Option D is incorrect because the delayed kinetics are inherent to entry blockade, not a sign of a dosing error.
11. A patient with chronic hepatitis B has surprisingly severe liver disease despite only modest HBV DNA levels, and emigrated from an HDV-endemic region. Integrating the clinical clue of disease severity disproportionate to HBV DNA with the limitations of standard testing, what is the appropriate diagnostic approach?
A) Test for anti-HDV antibody given the disproportionate severity and endemic-region origin, and confirm active infection with HDV RNA quantification, because anti-HDV IgG reflects exposure but does not distinguish active from resolved infection
B) No additional testing is needed because a standard hepatitis B panel already includes hepatitis D serology
C) Rely on anti-HDV IgG alone to establish active replication, since a positive IgG confirms ongoing infection
D) Order HDV RNA only if the surface antigen becomes negative, since hepatitis D cannot coexist with detectable surface antigen
E) Attribute the severity entirely to the HBV and pursue no further workup, since hepatitis D does not affect disease course
ANSWER: A
Rationale:
Hepatitis D is underdiagnosed because anti-HDV testing is not part of the routine hepatitis B workup. Disease severity disproportionate to the HBV DNA level, together with origin from an endemic region, are precisely the clues that should prompt anti-HDV testing; because anti-HDV IgG reflects exposure rather than active replication, confirmation requires HDV RNA quantification. The reasoning integrates the clinical clue with the limitation of antibody testing.
Option B: Option B is incorrect because standard hepatitis B panels do not routinely include hepatitis D serology, which is why the diagnosis is often missed.
Option C: Option C is incorrect because anti-HDV IgG alone cannot establish active replication; it does not distinguish active from resolved infection.
Option D: Option D is incorrect because hepatitis D requires the presence of hepatitis B surface antigen, so it coexists with detectable surface antigen rather than appearing only when it disappears.
Option E: Option E is incorrect because hepatitis D markedly worsens disease course and must not be ignored.
12. A patient presents 14 hours after a large acetaminophen ingestion. A colleague suggests N-acetylcysteine is now pointless because the optimal window has passed. Integrating the kinetics of acetaminophen metabolism in overdose with the mechanism of N-acetylcysteine, what is the most accurate response?
A) The colleague is correct; N-acetylcysteine has zero benefit beyond 8 hours and should be withheld
B) N-acetylcysteine is most effective within roughly 8 to 10 hours while NAPQI is still being generated and glutathione is not yet maximally depleted, but because overdose saturates conjugation and continues shunting acetaminophen through CYP2E1 to NAPQI, glutathione repletion still confers benefit later, so N-acetylcysteine should still be given at 14 hours
C) N-acetylcysteine should be delayed further until 24 hours, when it becomes maximally effective
D) The patient needs a single oral dose only, because intravenous therapy adds nothing after 8 hours
E) N-acetylcysteine should be withheld and the patient simply observed, since the liver will regenerate glutathione on its own
ANSWER: B
Rationale:
In overdose, the conjugation pathways saturate and a larger fraction of acetaminophen is shunted through CYP2E1 to NAPQI, depleting glutathione. N-acetylcysteine works by replenishing glutathione so residual NAPQI can be detoxified, and it is most effective early (about 8 to 10 hours). However, because NAPQI generation and glutathione depletion continue, benefit is reduced but not abolished later, so N-acetylcysteine should still be administered at 14 hours. The answer integrates overdose kinetics with the drug's mechanism.
Option A: Option A is incorrect because efficacy is diminished, not zero, beyond 8 hours.
Option C: Option C is incorrect because delaying therapy further reduces benefit; N-acetylcysteine does not become maximally effective at 24 hours.
Option D: Option D is incorrect because intravenous therapy remains appropriate and a single oral dose is not the standard, especially with aspiration concerns in toxic ingestions.
Option E: Option E is incorrect because withholding therapy forfeits the residual benefit; relying on spontaneous glutathione regeneration risks progression to liver failure.
13. A patient develops acute liver failure from an idiosyncratic drug reaction (non-acetaminophen) with grade II encephalopathy and a prothrombin time exceeding 100 seconds. Integrating the King's College Criteria with the evidence on N-acetylcysteine in non-acetaminophen acute liver failure, what is the most appropriate combined management decision?
A) Withhold N-acetylcysteine because it benefits only acetaminophen toxicity, and defer transplant evaluation until grade IV encephalopathy develops
B) Start N-acetylcysteine but do not contact a transplant center, since the King's College Criteria apply only to acetaminophen cases
C) Contact the transplant center only, and avoid N-acetylcysteine because it is ineffective once any encephalopathy is present
D) Recognize that a non-acetaminophen prothrombin time above 100 seconds meets a King's College Criterion prompting urgent transplant listing, and concurrently start intravenous N-acetylcysteine, whose transplant-free survival benefit in non-acetaminophen disease is greatest in early-grade (I-II) encephalopathy
E) Treat with high-dose corticosteroids as first-line, reserving N-acetylcysteine and transplant referral for later if steroids fail
ANSWER: D
Rationale:
This case requires integrating two threads. A prothrombin time above 100 seconds is itself a King's College Criterion for non-acetaminophen acute liver failure, prompting urgent transplant listing. Simultaneously, intravenous N-acetylcysteine improves transplant-free survival in non-acetaminophen acute liver failure, with the benefit concentrated in early-grade (I-II) encephalopathy — exactly this patient's stage — so both actions should occur together.
Option A: Option A is incorrect because N-acetylcysteine is now recommended in non-acetaminophen disease too, and waiting for grade IV encephalopathy to evaluate for transplant forfeits the window of greatest benefit.
Option B: Option B is incorrect because the King's College Criteria include a separate non-acetaminophen set, so transplant center contact is indicated.
Option C: Option C is incorrect because N-acetylcysteine is beneficial precisely in early-grade encephalopathy, not contraindicated once any encephalopathy appears.
Option E: Option E is incorrect because high-dose corticosteroids are not the established first-line therapy here, and delaying N-acetylcysteine and transplant referral is inappropriate.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.